tirzepatide buildleaf GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity glp-1 buildleaf BuildLeaf™ Tirzepatide GLP-1

Side effects above come from the current FDA prescribing information on DailyMed, accessed May 27, 2026: Foundayo (orforglipron), revised April 2026, and Wegovy (semaglutide injection and tablets), revised May 2026

showed that the core clock gene BMAL1 regulates EC proliferation by modulating cell-cycle regulators, particularly cyclin D1 (58)

Each kit includes everything you need with clear instructions and video guidance

Share your rotation pattern with your PlexusDx care team if you have questions about your technique

Side effects like nausea and constipation are dose-related and typically most noticeable during dose increases, but they usually improve within 23 weeks as your body adapts

While it is plausible biologically and supported by clinical trials that weight loss alone would decrease breast cancer risk, GLP-1 agonists are likely working through other pathways